Imetelstat Demonstrates Promising Efficacy in Myelofibrosis
December 11th 2013An investigator reported at the 55th annual meeting of the American Society of Hematology (ASH) that imetelstat, a telomerase inhibitor, has demonstrated significant activity in myelofibrosis, including complete responses.
Read More
Frontline Ofatumumab Efficacious in Older CLL Patients
December 11th 2013In patients with previously untreated chronic lymphocytic leukemia (CLL) who are considered inappropriate for fludarabine, the addition of ofatumumab to chlorambucil improves clinical outcomes and is tolerable irrespective of patient age or fitness.
Read More
Promising Ibrutinib Responses Demonstrated in Waldenström’s Macroglobulinemia
December 10th 2013Steven Treon, MD, PhD, reported that ibrutinib rapidly reduced serum immunoglobulin M (IgM) levels and improved hematocrit levels in patients with relapsed or refractory Waldenström’s macroglobulinemia (WM), and the responses to ibrutinib were durable.
Read More
First-in-Class Targeted Agent Shows Activity in Refractory Multiple Myeloma
December 10th 2013According to data presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans, a first-in-class targeted agent demonstrated activity in patients with relapsed and refractory multiple myeloma.
Read More
New Standard of Care Established in Newly Diagnosed Multiple Myeloma
December 9th 2013In patients with transplant-ineligible NDMM, the combination of continuous lenalidomide and low-dose dexamethasone (continuous Rd) extends PFS and trends toward improving OS compared with the standard combination of MPT.
Read More
Early Intervention in Smoldering Myeloma May Delay Progression
December 9th 2013CRs were seen in a group of high-risk patients following intervention in early or “smoldering†myeloma with a three-drug regimen, suggesting a window of opportunity that may delay or prevent progression to a debilitating disease state.
Read More
A Preview of the 2013 ASH Annual Meeting
December 5th 2013Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Alan N. Houghton Chair, Memorial Sloan-Kettering Cancer Center, highlights two studies that will be presented at the 2013 American Society of Hematology (ASH) Meeting.
Read More
T-DM1 in Previously Treated HER2+ Metastatic Breast Cancer
September 12th 2013An analysis of the T-PAS expanded access study of T-DM1 in previously treated HER2+ metastatic breast cancer confirmed existing information on the safety of the combination, and observed significant clinical activity in a patient population that averaged seven prior therapies.
Read More
An Expanded Access Study of T-DM1 in Previously Treated HER2-Positive Metastatic Breast Cancer
September 12th 2013Denise A. Yardley, MD, Senior Investigator, Sarah Cannon Research Institute, discusses an expanded access study of T-DM1 in previously treated HER2-positive metastatic breast cancer.
Read More